FDA Seeks Comments on Lab Rules for Pre-Market Product Studies
Published Date: 11/19/2026
Notice
Summary
The FDA is asking for public feedback on extending rules that make sure lab studies on food additives, drugs, and medical devices are done right and safely. This affects companies testing products before they hit the market, helping protect consumers without adding new costs. Comments are open until December 21, 2026, so now’s the time to weigh in!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
GLP Recordkeeping and Reporting Continued
If you sponsor or run nonclinical laboratory studies for products regulated by FDA (food additives, human drugs and biological products, animal drugs, or medical devices), you must continue to follow the Good Laboratory Practice rules in 21 CFR part 58 and retain required records and prepare final study reports. FDA estimates there are 300 respondents and that the collection requires 517,849 annual reporting hours and 786,308 annual recordkeeping hours in total across respondents.
No Capital or O&M Costs for GLP Collection
FDA states there are no capital costs or operating and maintenance (O&M) costs associated with this information collection (OMB control number 0910-0119). The agency is retaining the currently approved burden estimates rather than adding new cost categories.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-23351, Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition
The FDA wants to officially say that N-acetyl-L-cysteine (NAC) can be sold as a dietary supplement. This means companies can legally put NAC in their products without breaking the rules, as long as they follow other laws. People and businesses making or selling supplements with NAC should share their thoughts by January 19, 2027.
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
Previous / Next Documents
Previous: 2026-23540, Medicare and Medicaid Programs; Quarterly Listing of Program Issuances-July Through September 2026
This notice shares all the important updates and rules CMS rolled out from July to September 2026 for Medicare and Medicaid. If you’re a healthcare provider, patient, or policy watcher, these changes could affect how services are covered and paid for, with some updates possibly impacting costs or deadlines. Need details? CMS has contacts ready to help you navigate the new info!
Next: 2026-23542, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; National Youth Tobacco Survey
The FDA is updating its National Youth Tobacco Survey for 2027-2029 to keep track of tobacco use among young people across the U.S. This helps the FDA fight youth tobacco use and protect kids from harmful products. They’re asking for public comments by December 21, 2026, so everyone can weigh in before the survey moves forward.